Two other peptide vaccines against mIDH1 are being studied: PEPIDH1M in patients with recurrent grade 2 gliomas (RESIST trial NCT02193347) and IDH1 R132H dendritic cell vaccine in patients with IDH mutant gliomas (NCT02771301). The gene discussed is IDH1; the disease is central nervous system cancer.